NCT04873375View on ClinicalTrials.gov

Cemiplimab for Secondary Angiosarcomas

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

October 9, 2024

Study Completion Date

October 18, 2024

Conditions
Secondary AngiosarcomaLocally Advanced SarcomaMetastasis
Interventions
DRUG

Cemiplimab

After inclusion patients will be treated with Cemiplimab 350mg intravenously every three weeks

Trial Locations (1)

6525AG

RadboudUMC, Nijmegen

All Listed Sponsors
collaborator

Genzyme Europe B.V.

UNKNOWN

lead

Radboud University Medical Center

OTHER

NCT04873375 - Cemiplimab for Secondary Angiosarcomas | Biotech Hunter | Biotech Hunter